Faraday Pharmaceuticals Stock

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.

Sign up today and learn more about Faraday Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Faraday Pharmaceuticals Stock

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

Funding History

September 2015$30.0M
February 2017$33.0M
September 2019$25.0M
November 2022$52.8M

Management

CEO

Stephen A. Hill

General Counsel & Corporate Secretary

Patrick C. Rock

Vice President Regulatory Affairs and Quality

Tressa D. Randall

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo